Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price objective lifted by equities research analysts at JMP Securities from $63.00 to $125.00 in a note issued to investors on Wednesday, The Fly reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. JMP Securities’ price target points to a potential upside of 169.98% from the stock’s current price.

A number of other research firms also recently weighed in on MDGL. Roth Capital started coverage on shares of Madrigal Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $62.00 price target on the stock. HC Wainwright lifted their price target on shares of Madrigal Pharmaceuticals from $54.00 to $105.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Evercore ISI started coverage on shares of Madrigal Pharmaceuticals in a research note on Friday, September 22nd. They set an “outperform” rating and a $65.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Madrigal Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $94.25.

Madrigal Pharmaceuticals (NASDAQ:MDGL) traded down $1.68 on Wednesday, reaching $46.30. 86,700 shares of the company’s stock were exchanged, compared to its average volume of 44,074. Madrigal Pharmaceuticals has a 1 year low of $13.09 and a 1 year high of $53.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.79) by $0.11. equities analysts forecast that Madrigal Pharmaceuticals will post -2.57 EPS for the current fiscal year.

Several large investors have recently modified their holdings of MDGL. Renaissance Technologies LLC boosted its stake in shares of Madrigal Pharmaceuticals by 0.7% in the 1st quarter. Renaissance Technologies LLC now owns 57,875 shares of the biopharmaceutical company’s stock valued at $891,000 after purchasing an additional 400 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Madrigal Pharmaceuticals in the 1st quarter valued at $321,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter valued at $225,000. Bank of New York Mellon Corp acquired a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter valued at $179,000. Finally, Shikiar Asset Management Inc. acquired a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter valued at $246,000. Institutional investors own 21.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/06/madrigal-pharmaceuticals-mdgl-pt-raised-to-125-00.html.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

The Fly

Receive News & Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.